CJC-1295 reported effects and safety.

The short version

CJC-1295 is a research-chemical GHRH analog that stimulates the pituitary to release growth hormone (GH) and, in turn, raises IGF-1 — a growth-related signaling protein — for days with each dose. It is not approved for human use anywhere. The published human evidence is limited to early pharmacology studies in healthy volunteers; there is no clinical trial measuring whether it actually improves body composition, recovery, or any other outcome in otherwise-healthy adults ^[2].

What follows is two things: first, a plain account of effects that people in research-use communities commonly describe (labeled explicitly as anecdotal, not clinical evidence); second, safety cautions grounded in mechanism, published literature, and regulatory findings. Both layers are necessary for anyone trying to read the CJC-1295 evidence honestly.

What people report

These accounts are anecdotal, not clinical evidence. They come from peptide-user forums, consumer drug review sites, and wellness-clinic summaries of user feedback — not from controlled trials. Effects vary substantially between individuals, and no dose is specified or implied.

Benefits reported:

• Deeper, more restful sleep — very commonly reported, and often the first thing people notice. Users describe falling asleep faster, staying asleep longer, and waking feeling more rested. The biology is consistent: growth hormone is released mainly during deep sleep, and GHRH-axis stimulation could plausibly support that pattern ^[15].
• Faster recovery from training and soreness — frequently reported. People in fitness communities say they recover more quickly between hard sessions and feel less lingering soreness. This is anecdotal; whether it reflects a direct effect or simply better sleep is not distinguishable from user reports.
• Gradual fat loss, especially around the midsection — frequently reported, typically described as slow and showing up around weeks three to six rather than quickly. Nearly all accounts note it is present only alongside diet and exercise. These are personal impressions, not clinical measurements.
• Leaner look and better muscle retention — frequently reported, described as a subtle shift over time rather than dramatic gain. People note it is contingent on consistent training.
• More daytime energy and stamina — occasionally reported. Many link it to sleeping better. Reports are inconsistent; other users notice no energy change.
• Improved focus and mental clarity — occasionally reported, usually attributed to improved sleep and recovery rather than a direct brain effect.
• Firmer skin and connective-tissue feel — occasionally reported, typically framed as an anti-aging impression. These are subjective and hard to separate from other variables.

Adverse effects reported:

• Water retention, bloating, and puffiness — very commonly reported, and the most common downside. Users describe mild bloating, a heavier feeling, or puffiness in the hands and face. Communities note this is more pronounced with the long-acting DAC form than with the short-acting no-DAC form, because the DAC variant keeps GH elevated for days. Most reports say it eases over a few weeks.
• Tingling or numbness in the hands and fingers — frequently reported, often compared to mild carpal tunnel. Usually attributed to fluid retention pressing on wrist nerves; typically described as dose-related and reversible.
• Injection-site reactions — frequently reported, described as minor redness, itching, or soreness at the injection spot, usually short-lived.
• Flushing or a warm head rush after injecting — occasionally reported, especially with the short-acting no-DAC form. Passes within minutes.
• Fatigue, drowsiness, or lethargy — occasionally reported, sometimes soon after dosing. Reports conflict: other users report more energy. The effect is not universal.
• Headache — occasionally reported, described as mild and short-lived.
• Increased appetite — occasionally reported, and mainly when CJC-1295 is paired with ipamorelin, which acts on the ghrelin (hunger) pathway. Rarely reported with CJC-1295 alone.
• Higher blood sugar or reduced insulin sensitivity — occasionally reported, particularly by users tracking glucose. Growth hormone is glucose-sparing, so sustained GH-axis stimulation can reduce insulin sensitivity. People with existing blood-sugar concerns note this most often.

Safety and cautions

Not approved for human use. CJC-1295 has never been approved by the FDA or any major regulator. Published human evidence is limited to early pharmacology studies in a small number of healthy volunteers; there are no large or long-term safety trials in healthy adults ^[2][15]. A 2026 review of unapproved peptide therapies described the human evidence base as insufficient to characterize long-term safety ^[15].

Sustained IGF-1 elevation and theoretical cancer risk. CJC-1295 raises both GH and IGF-1 for days with each dose. A large collaborative meta-analysis associated higher circulating IGF-1 with a modestly increased risk of certain cancers ^[16]. The link is epidemiologic association, not proof that this compound causes cancer; but the association is an established finding in the literature, and anyone with a personal or family history of cancer should regard sustained IGF-1 elevation as a mechanism-based concern.

Fluid retention and nerve-compression effects. Growth hormone makes the kidneys retain sodium and water, expanding fluid volume ^[17]. This is the mechanism behind the water retention and carpal-tunnel-like tingling that users commonly report. For people prone to swelling, high blood pressure, or cardiac strain, fluid expansion is a real physiological concern, not only a cosmetic one.

Effects on blood sugar and insulin sensitivity. Growth hormone is glucose-sparing. A clinical study of a GHRH analog documented effects on GH pulsatility and insulin sensitivity, supporting the theoretical concern that sustained GH-axis stimulation can reduce insulin sensitivity and raise blood sugar ^[18]. People with diabetes, prediabetes, or insulin resistance have the most reason to be cautious.

Immunogenicity flagged by the FDA. FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity — the risk that the body forms an immune response to the peptide — as one basis for not recommending CJC-1295 for the 503A compounding bulks list ^[8]. A current Nature Reviews Endocrinology review of GHRH analogs reinforces that long-acting, albumin-binding peptide designs carry such considerations ^[19]. This is a regulator-level concern, not a settled clinical finding.

Discontinued development and a cited patient death. The original CJC-1295 DAC development program ran a Phase 2 trial that was stopped in October 2006 after a participant died of an acute coronary event. An independent review judged the death unrelated to study drug. The public record does not establish causality ^[3]. The relevant point is that the program never advanced to approval, and long-term safety was never established in any trial.

DAC and no-DAC forms are routinely confused. Many sources treat 'CJC-1295 DAC' and 'Modified GRF 1-29' (the short-acting no-DAC form) as interchangeable. They are not: the DAC form stays active for up to eight days, while the no-DAC form clears in roughly 30 minutes ^[1][20]. This distinction matters for safety. The DAC form drives more sustained fluid retention, blood-sugar shifts, and IGF-1 exposure than the no-DAC form.

Prohibited in sport. CJC-1295 is banned by the World Anti-Doping Agency at all times under Section S2 (peptide hormones, growth factors, and related substances) ^[9]. Detection methods are validated and in routine use ^[10]. Any tested athlete who uses it faces an anti-doping violation.